How much did ImpediMed achieve in EBIT for the current year?
In the current year, ImpediMed has achieved an EBIT of -21.22 M AUD.
ImpediMed EBIT 2024
ImpediMed EBIT
-21.22 M AUD
Ticker
IPD.AX
ISIN
AU000000IPD8
In 2024, ImpediMed's EBIT was -21.22 M AUD, a -0.16% increase from the -21.26 M AUD EBIT recorded in the previous year.
The ImpediMed EBIT history
| YEAR | EBIT (undefined AUD) |
|---|---|
| 2028e | - |
| 2027e | 12.29 |
| 2026e | -7.13 |
| 2025e | -14.59 |
| 2024 | -21.22 |
| 2023 | -21.26 |
| 2022 | -19.85 |
| 2021 | -21.23 |
| 2020 | -22.9 |
| 2019 | -24.31 |
| 2018 | -27.65 |
| 2017 | -27.5 |
| 2016 | -23.66 |
| 2015 | -14.8 |
| 2014 | -7.95 |
| 2013 | -8.42 |
| 2012 | -12.71 |
| 2011 | -11.91 |
| 2010 | -11.34 |
| 2009 | -13.68 |
| 2008 | -8.06 |
| 2007 | -7 |
| 2006 | -4.94 |
| 2005 | -3.23 |
ImpediMed Revenue, EBIT, Net Income AU000000IPD8 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into ImpediMed, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ImpediMed from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ImpediMed’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of ImpediMed. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into ImpediMed’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing ImpediMed’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ImpediMed’s growth potential.
ImpediMed Revenue, EBIT and net profit per share
| Date | ImpediMed Revenue | ImpediMed EBIT | ImpediMed Net Income |
|---|---|---|---|
| 2028e | 68.58 M AUD | 0 AUD | 0 AUD |
| 2027e | 46.87 M AUD | 12.29 M AUD | -674,295.9 AUD |
| 2026e | 27.19 M AUD | -7.13 M AUD | -3.06 M AUD |
| 2025e | 16.06 M AUD | -14.59 M AUD | -18.39 M AUD |
| 2024 | 10.32 M AUD | -21.22 M AUD | -19.79 M AUD |
| 2023 | 11.34 M AUD | -21.26 M AUD | -20.52 M AUD |
| 2022 | 10.57 M AUD | -19.85 M AUD | -19.87 M AUD |
| 2021 | 8.41 M AUD | -21.23 M AUD | -20.71 M AUD |
| 2020 | 5.74 M AUD | -22.9 M AUD | -21.38 M AUD |
| 2019 | 4.16 M AUD | -24.31 M AUD | -24.12 M AUD |
| 2018 | 3.32 M AUD | -27.65 M AUD | -27.37 M AUD |
| 2017 | 6.13 M AUD | -27.5 M AUD | -27.57 M AUD |
| 2016 | 5.95 M AUD | -23.66 M AUD | -25.98 M AUD |
| 2015 | 4.93 M AUD | -14.8 M AUD | -14.8 M AUD |
| 2014 | 3.58 M AUD | -7.95 M AUD | -7.94 M AUD |
| 2013 | 2.93 M AUD | -8.42 M AUD | -8.46 M AUD |
| 2012 | 3.18 M AUD | -12.71 M AUD | -12.34 M AUD |
| 2011 | 4.17 M AUD | -11.91 M AUD | -14.82 M AUD |
| 2010 | 3.81 M AUD | -11.34 M AUD | -11.4 M AUD |
| 2009 | 3.27 M AUD | -13.68 M AUD | -14.03 M AUD |
| 2008 | 2.99 M AUD | -8.06 M AUD | -9.76 M AUD |
| 2007 | 1.94 M AUD | -7 M AUD | -10.13 M AUD |
| 2006 | 1.08 M AUD | -4.94 M AUD | -7.58 M AUD |
| 2005 | 440,000 AUD | -3.23 M AUD | -3.19 M AUD |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 440,000 AUD | -3.23 M AUD | -3.19 M AUD |
| 2006 | 1.08 M AUD | -4.94 M AUD | -7.58 M AUD |
| 2007 | 1.94 M AUD | -7 M AUD | -10.13 M AUD |
| 2008 | 2.99 M AUD | -8.06 M AUD | -9.76 M AUD |
| 2009 | 3.27 M AUD | -13.68 M AUD | -14.03 M AUD |
| 2010 | 3.81 M AUD | -11.34 M AUD | -11.4 M AUD |
| 2011 | 4.17 M AUD | -11.91 M AUD | -14.82 M AUD |
| 2012 | 3.18 M AUD | -12.71 M AUD | -12.34 M AUD |
| 2013 | 2.93 M AUD | -8.42 M AUD | -8.46 M AUD |
| 2014 | 3.58 M AUD | -7.95 M AUD | -7.94 M AUD |
| 2015 | 4.93 M AUD | -14.8 M AUD | -14.8 M AUD |
| 2016 | 5.95 M AUD | -23.66 M AUD | -25.98 M AUD |
| 2017 | 6.13 M AUD | -27.5 M AUD | -27.57 M AUD |
| 2018 | 3.32 M AUD | -27.65 M AUD | -27.37 M AUD |
| 2019 | 4.16 M AUD | -24.31 M AUD | -24.12 M AUD |
| 2020 | 5.74 M AUD | -22.9 M AUD | -21.38 M AUD |
| 2021 | 8.41 M AUD | -21.23 M AUD | -20.71 M AUD |
| 2022 | 10.57 M AUD | -19.85 M AUD | -19.87 M AUD |
| 2023 | 11.34 M AUD | -21.26 M AUD | -20.52 M AUD |
| 2024 | 10.32 M AUD | -21.22 M AUD | -19.79 M AUD |
| 2025e | 16.06 M AUD | -14.59 M AUD | -18.39 M AUD |
| 2026e | 27.19 M AUD | -7.13 M AUD | -3.06 M AUD |
| 2027e | 46.87 M AUD | 12.29 M AUD | -674,295.9 AUD |
| 2028e | 68.58 M AUD | 0 AUD | 0 AUD |
ImpediMed stock margins AU000000IPD8 ·
The ImpediMed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ImpediMed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ImpediMed.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the ImpediMed's sales revenue. A higher gross margin percentage indicates that the ImpediMed retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the ImpediMed's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the ImpediMed's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ImpediMed's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ImpediMed. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ImpediMed's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
ImpediMed Margin History
| ImpediMed Gross margin | ImpediMed Profit margin | ImpediMed EBIT margin | ImpediMed Profit margin |
|---|---|---|---|
| 2028e | 87.27 % | 0 % | 0 % |
| 2027e | 87.27 % | 26.21 % | -1.44 % |
| 2026e | 87.27 % | -26.21 % | -11.27 % |
| 2025e | 87.27 % | -90.81 % | -114.49 % |
| 2024 | 87.27 % | -205.67 % | -191.78 % |
| 2023 | 86.37 % | -187.39 % | -180.9 % |
| 2022 | 83.83 % | -187.84 % | -188.09 % |
| 2021 | 80.95 % | -252.46 % | -246.24 % |
| 2020 | 70.77 % | -398.95 % | -372.36 % |
| 2019 | 69.87 % | -584.94 % | -580.44 % |
| 2018 | 70.58 % | -833.36 % | -824.95 % |
| 2017 | 75.72 % | -448.44 % | -449.55 % |
| 2016 | 73.38 % | -397.85 % | -436.86 % |
| 2015 | 73.13 % | -300.45 % | -300.32 % |
| 2014 | 59.78 % | -222.07 % | -221.79 % |
| 2013 | 59.73 % | -287.37 % | -288.74 % |
| 2012 | 60.38 % | -399.69 % | -388.05 % |
| 2011 | 60.43 % | -285.61 % | -355.4 % |
| 2010 | 57.74 % | -297.64 % | -299.21 % |
| 2009 | 55.35 % | -418.35 % | -429.05 % |
| 2008 | 76.92 % | -269.57 % | -326.42 % |
| 2007 | 67.53 % | -360.82 % | -522.16 % |
| 2006 | 50.93 % | -457.41 % | -701.85 % |
| 2005 | 63.64 % | -734.09 % | -725 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 63.64 % | -734.09 % | -725 % |
| 2006 | 50.93 % | -457.41 % | -701.85 % |
| 2007 | 67.53 % | -360.82 % | -522.16 % |
| 2008 | 76.92 % | -269.57 % | -326.42 % |
| 2009 | 55.35 % | -418.35 % | -429.05 % |
| 2010 | 57.74 % | -297.64 % | -299.21 % |
| 2011 | 60.43 % | -285.61 % | -355.4 % |
| 2012 | 60.38 % | -399.69 % | -388.05 % |
| 2013 | 59.73 % | -287.37 % | -288.74 % |
| 2014 | 59.78 % | -222.07 % | -221.79 % |
| 2015 | 73.13 % | -300.45 % | -300.32 % |
| 2016 | 73.38 % | -397.85 % | -436.86 % |
| 2017 | 75.72 % | -448.44 % | -449.55 % |
| 2018 | 70.58 % | -833.36 % | -824.95 % |
| 2019 | 69.87 % | -584.94 % | -580.44 % |
| 2020 | 70.77 % | -398.95 % | -372.36 % |
| 2021 | 80.95 % | -252.46 % | -246.24 % |
| 2022 | 83.83 % | -187.84 % | -188.09 % |
| 2023 | 86.37 % | -187.39 % | -180.9 % |
| 2024 | 87.27 % | -205.67 % | -191.78 % |
| 2025e | 87.27 % | -90.81 % | -114.49 % |
| 2026e | 87.27 % | -26.21 % | -11.27 % |
| 2027e | 87.27 % | 26.21 % | -1.44 % |
| 2028e | 87.27 % | 0 % | 0 % |
ImpediMed Aktienanalyse
What does ImpediMed do?
ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing ImpediMed's EBIT
ImpediMed's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of ImpediMed's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
ImpediMed's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in ImpediMed’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about ImpediMed stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company ImpediMed.
How has the EBIT of ImpediMed developed in recent years?
The EBIT of ImpediMed has increased by -0.16% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company ImpediMed?
The EBIT of ImpediMed is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does ImpediMed pay?
Over the past 12 months, ImpediMed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImpediMed is expected to pay a dividend of 0 AUD.
What is the dividend yield of ImpediMed?
The current dividend yield of ImpediMed is .
When does ImpediMed pay dividends?
ImpediMed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImpediMed?
ImpediMed paid dividends every year for the past 0 years.
What is the dividend of ImpediMed?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImpediMed located?
ImpediMed is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImpediMed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImpediMed from 11/4/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 11/4/2024.
When did ImpediMed pay the last dividend?
The last dividend was paid out on 11/4/2024.
What was the dividend of ImpediMed in the year 2023?
In the year 2023, ImpediMed distributed 0 AUD as dividends.
In which currency does ImpediMed pay out the dividend?
The dividends of ImpediMed are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von ImpediMed
Our stock analysis for ImpediMed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImpediMed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
